Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Brii Bio Delivers First Head-to-Head Comparison of siRNA (Elebsiran) and PEG-IFNα Combination versus PEG-IFNα Alone at AASLD's The Liver Meeting® 2024, Demonstrating Higher Loss of HBV Surface Antigen by Combining with siRNA 2024-11-19 19:30
Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL™ Congress 2024 2024-06-07 19:00
Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies 2024-05-14 07:27
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results 2024-03-22 19:00
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies 2024-02-14 08:07
Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer 2024-01-03 20:00
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023 2023-11-14 06:40
Brii Bio Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2023 2023-11-14 06:40
Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination with PEG-IFNα for the Treatment of Chronic Hepatitis B 2023-09-06 18:45
Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results 2023-08-22 22:00
Brii Biosciences Broadens its Leadership in Hepatitis B with a Portfolio Now Addressing Disease's Burdens from Prevention to Cure 2023-07-06 07:25
Brii Biosciences Provides Latest Clinical Development and Corporate Updates 2023-07-06 07:19
Brii Bio Announces New Data from Partners Underscoring Potential for HBV Functional Cure at EASL™ Congress 2023 2023-06-25 20:00
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders 2023-06-01 08:00
Brii Bio Publishes 2022 Environmental, Social and Governance Report 2023-04-28 09:00
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial Results 2023-03-24 13:33
Brii Biosciences Provides Update on Strategic Clinical Development Progress 2022-12-27 20:00
Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022 2022-10-19 20:00
Brii Biosciences Announces Top-line Results from Phase 1 Study of BRII-296, A Long-Acting Therapy in Development for Postpartum Depression 2022-09-26 20:00
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum 2022-09-01 07:30
1 2